Abdul Halim Abdul Gafor
Overview
Explore the profile of Abdul Halim Abdul Gafor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sualeheen A, Khor B, Balasubramanian G, Sahathevan S, Chinna K, Mat Daud Z, et al.
J Ren Nutr
. 2022 Feb;
32(6):726-738.
PMID: 35182714
Objectives: This study modified Healthy Eating Index (HEI) based on hemodialysis (HD)-specific nutritional guidelines and investigated associations between the diet quality (DQ) and nutritional risk in HD patients. Methods: The...
12.
Azami N, Abdul Murad N, Mohammed Nawi A, Salleh S, Periyasamy P, Kori N, et al.
J Infect Dev Ctries
. 2022 Jan;
15(12):1816-1824.
PMID: 35044938
Introduction: During the second wave of the coronavirus disease 19 (COVID-19) pandemic, Malaysia reported several COVID-19 clusters related to healthcare workers. Thus, addressing and understanding the risk of exposure in...
13.
Sahathevan S, Karupaiah T, Khor B, Sadu Singh B, Mat Daud Z, Fiaccadori E, et al.
Front Nutr
. 2022 Jan;
8:743324.
PMID: 34977109
Muscle wasting, observed in patients with end-stage kidney disease and protein energy wasting (PEW), is associated with increased mortality for those on hemodialysis (HD). Oral nutritional supplementation (ONS) and nutrition...
14.
Ng H, Khor B, Sahathevan S, Sualeheen A, Chinna K, Gafor A, et al.
Qual Life Res
. 2021 Nov;
31(5):1441-1459.
PMID: 34748139
Purpose: To identify relationships between health-related quality of life (HRQOL) and nutritional status in hemodialysis (HD) patients. Method: Secondary data from a cross-sectional survey was utilized. HRQOL was assessed for...
15.
Ahmad N, Mohd Ali N, Mohammed Nawi A, Hassan M, Aizuddin A, Hod R, et al.
J Infect Dev Ctries
. 2021 Sep;
15(8):1059-1065.
PMID: 34516411
Introduction: Information on the clinical characteristics of local patients with confirmed COVID-19 is limited. This study aims to report the clinical characteristics of 147 patients admitted and receiving treatment at...
16.
Khor B, Tiong H, Tan S, Wong S, Chin K, Karupaiah T, et al.
PLoS One
. 2021 Jul;
16(7):e0255205.
PMID: 34297765
Studies investigating the effects of tocotrienols on inflammation and oxidative stress have yielded inconsistent results. This systematic review and meta-analysis aimed to evaluate the effects of tocotrienols supplementation on inflammatory...
17.
Sahathevan S, Khor B, Yeong C, Tan T, Meera Mohaideen A, Ng H, et al.
JPEN J Parenter Enteral Nutr
. 2021 Jun;
45(5):872-873.
PMID: 34165200
No abstract available.
18.
Sadu Singh B, Narayanan S, Khor B, Sahathevan S, Gafor A, Fiaccadori E, et al.
Front Pharmacol
. 2021 May;
12:663960.
PMID: 33935786
No abstract available.
19.
Lee F, Islahudin F, Ali Nasiruddin A, Gafor A, Wong H, Bavanandan S, et al.
J Pers Med
. 2021 Apr;
11(4).
PMID: 33808503
Personalised medicine is potentially useful to delay the progression of chronic kidney disease (CKD). The aim of this study was to determine the effects of CYP3A5 polymorphism in rapid CKD...
20.
van der Aart-van der Beek A, Koomen J, Dekkers C, Barbour S, Boulton D, Gansevoort R, et al.
Clin Pharmacokinet
. 2021 Feb;
60(4):517-525.
PMID: 33587286
Background And Objective: Dapagliflozin, a sodium-glucose co-transporter inhibitor, was originally developed as an oral glucose-lowering drug for the treatment of type 2 diabetes mellitus. Emerging data suggest that cardiovascular and...